Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells

• Published in: World journal of gastroenterology : WJG 2007-04, Vol.13 (16), p.2324-2327
• Main Authors: Li, Gui-Qiu, Xu, Wei-Zhen, Wang, Jing-Xia, Deng, Wen-Wei, Li, Di, Gu, Hong-Xi
• Format: Article
• Language: English
• Subjects: Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - virology; Cell Line, Tumor; DNA Replication - drug effects; DNA, Viral - metabolism; Drug Therapy, Combination; Hepatitis B - drug therapy; Hepatitis B e Antigens - metabolism; Hepatitis B Surface Antigens - metabolism; Hepatitis B virus - genetics; Hepatitis B virus - physiology; Humans; Lamivudine - pharmacology; Lamivudine - therapeutic use; Liver Neoplasms - pathology; Liver Neoplasms - virology; Rapid Communication; RNA, Messenger - metabolism; RNA, Small Interfering - pharmacology; RNA, Small Interfering - therapeutic use; RNA, Viral - metabolism; Transfection; Virus Replication - drug effects
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v13.i16.2324

To observe the inhibition of hepatitis B virus (HBV) replication and expression by combination of siRNA and lamivudine in HepG2.2.15 cells. Recombinant plasmid psil-HBV was constructed and transfected into HepG2.2.15 cells. The transfected cells were cultured in lamivudine-containing medium (0.05 micromol/L) and harvested at 48, 72 and 96 h. The concentration of HBeAg and HBsAg was determined using ELISA. HBV DNA replication was examined by real-time PCR and the level of HBV mRNA was measured by RT-PCR. In HepG2.2.15 cells treated with combination of siRNA and lamivudine, the secretion of HBeAg and HBsAg into the supernatant was found to be inhibited by 91.80% and 82.40% (2.89+/-0.48 vs 11.73+/-0.38, P